EBS— Emergent BioSolutions Inc.

MaterialsBiotechnology$229M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenues	$742.9M-28.8%	$1.04B-0.5%	$1.05B+8.6%	$966.2M
Cost of product and services sales, net	$326.2M-52.1%	$681.3M-3.4%	$705.4M+162.7%	$268.5M
Research and development	$53.2M-24.8%	$70.7M-36.5%	$111.4M-40.8%	$188.3M
Selling, general and administrative	$186.1M-39.6%	$308.0M-16.4%	$368.4M+8.5%	$339.5M
Amortization of intangible assets	$65.1M+0.0%	$65.1M-0.8%	$65.6M+9.5%	$59.9M
Goodwill impairment	$0	$0-100.0%	$218.2M+3156.7%	$6.7M
Impairment of long-lived assets	$12.2M-55.1%	$27.2M-91.1%	$306.7M	$0
Total operating expenses	$642.8M-44.2%	$1.15B-35.1%	$1.78B+37.9%	$1.29B
Income (loss) from operations	$100.1M+192.1%	-$108.7M+85.0%	-$726.4M-327.3%	-$170.0M
Interest expense	-$59.3M+16.5%	-$71.0M+19.2%	-$87.9M-135.7%	-$37.3M
Gain on sale of business	$0-100.0%	$24.3M-67.3%	$74.2M	$0
Gain (loss) on extinguishments of debt	-$12.2M-2133.3%	$600K-76.0%	$2.5M	—
Other, net	$54.2M+355.5%	$11.9M+85.9%	$6.4M+154.7%	-$11.7M
Total other income (expense), net	-$17.3M+49.4%	-$34.2M-612.5%	-$4.8M+90.2%	-$49.0M
Income (loss) before income taxes	$82.8M+157.9%	-$142.9M+80.5%	-$731.2M-233.9%	-$219.0M
Income tax provision	$30.2M-36.7%	$47.7M+62.8%	$29.3M+495.9%	-$7.4M
Net income (loss)	$52.6M+127.6%	-$190.6M+74.9%	-$760.5M-259.4%	-$211.6M
Basic (in dollars per share)	$980000.00+127.2%	-$3600000.00+75.8%	-$14850000.00-251.9%	-$4220000.00
Diluted (in dollars per share)	$930000.00+125.8%	-$3600000.00+75.8%	-$14850000.00-251.9%	-$4220000.00
Basic (in shares)	53.5M+0.9%	53.0M+3.5%	51.2M+2.2%	50.1M
Diluted (in shares)	56.7M+7.0%	53.0M+3.5%	51.2M+2.2%	50.1M
Product and services sales, net
Contracts and grants

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.